CM
BIOT

Cohanzick Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Cohanzick Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-799,001
Closed -$7.93M – 255
2022
Q3 		$7.93M Hold
799,001
– – 1.92% 9
2022
Q2 		$7.91M Hold
799,001
– – 2.24% 7
2022
Q1 		$7.88M Hold
799,001
– – 1.78% 9
2021
Q4 		$7.86M Buy
+799,001
New +$7.84M 1.39% 13

Other funds holding BIOT

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Cohanzick Management's BIOT Position: Q4 2022 in Review

Cohanzick Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q4 2022, closing a stake of 799,001 shares — an estimated $7.93M sold.

Cohanzick Management first reported a position in BIOT in Q4 2021 and held it in 4 quarters. The position peaked at $7.93M in Q3 2022. 68 funds tracked by Wall St. Rank hold BIOT as of Q4 2022.

  • Cohanzick Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Cohanzick Management sold 799,001 Biotech Acquisition Company Class A Ordinary Shares shares in Q4 2022, an estimated $7.93M.
  • Cohanzick Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • Cohanzick Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $7.93M in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q4 2022.

Based on Cohanzick Management's 13F filing for Q4 2022, filed 13 Feb 2023.